SHIJ

CSPC Pharmaceutical Group is a leading integrated pharmaceutical enterprise in China, specializing in the research, development, manufacturing, and marketing of innovative drugs and active pharmaceutical ingredients. The company maintains a strong market position in therapeutic areas such as oncology, cardiovascular disease, neurology, and anti-infectives, with flagship products like NBP (butylphthalide) for stroke. CSPC has transitioned from a generic-focused manufacturer to an innovation-driven biotech powerhouse, leveraging advanced platforms in nanotechnology, antibody-drug conjugates (ADCs), and mRNA vaccines. With a robust pipeline and extensive manufacturing capabilities, the group serves both domestic and international markets, consistently ranking among the top pharmaceutical companies in China.